PTC Therapeutics, Inc. (NASDAQ:PTCT) Q2 2023 Earnings Call Transcript

Page 13 of 13

Kylie O’Keefe: Yes, absolutely. Thanks. I think one of the things Paul that we’re seeing with Evrysdi is we’re continuing to see the growth in total patients treated. And this is being driven by a number of different factors across the board. It’s being driven by continued switches coming from both Zolgensma and Spinraza as well as continued therapy-naive patients being treated. In the US, you’ve also heard Roche talk about the infant starting to be an increasing patient segment that we’re seeing for Evrysdi-treated patients. And with the recent CHMP opinion, we also expect this trend to continue ex-U.S. They have also talked about the fact that they are global market leaders — or sorry they are market leaders in most major markets around the world and expect to be global market leader by the end of 2023.

I think one of the things that you do see with Evrysdi, which is consistent to what we see with Translarna and what Eric touched on throughout this call is lumpiness to the business. And that’s directly related to the international business. Like us they have large government-based purchase orders that fluctuate throughout the different quarters and so it is expected that you will see that quarter-over-quarter lumpiness. I think we’ve seen growth from 2022 into Q1 of 2023 with a little bit of lumpiness in Q2 but we expect the growth to continue throughout the rest of the year. I think we’re in a good position for the $100 million milestone that you touched on. If you look at sales through the first half of the year we’re past halfway. So that’s a really positive sign.

And so from that perspective that’s why we remain confident with the full revenue guidance for 2023 including that $100 million milestone. So just lumpiness that we see across our Translarna business as well.

Paul Choi: Okay. Great. Thank you for the color.

Operator: Thank you. I am showing no further questions. I would now like to turn the call back over to Dr. Matthew Klein for closing remarks.

Matthew Klein: Thank you again for joining us on the call today. I’m extremely proud of our many achievements in the second quarter and we look forward to a busy and productive second half of 2023. So thank you all again for joining the call and have a good evening.

Operator: This concludes today’s conference call. Thank you for participating. You may now disconnect.

Follow Ptc Therapeutics Inc. (NASDAQ:PTCT)

Page 13 of 13